Cargando…
Analytical performance of a new automated chemiluminescent magnetic immunoassays for soluble PD-1, PD-L1, and CTLA-4 in human plasma
Current clinically approved biomarkers for the PD-1 blockade cancer immunotherapy are based entirely on the properties of tumour cells. With increasing awareness of clinical responses, more precise biomarkers for the efficacy are required based on immune properties. In particular, expression levels...
Autores principales: | Goto, Megumi, Chamoto, Kenji, Higuchi, Keiko, Yamashita, Saya, Noda, Kenta, Iino, Takuya, Miura, Masahiro, Yamasaki, Toshinari, Ogawa, Osamu, Sonobe, Makoto, Date, Hiroshi, Hamanishi, Junzo, Mandai, Masaki, Tanaka, Yoshimasa, Chikuma, Shunsuke, Hatae, Ryusuke, Muto, Manabu, Minamiguchi, Sachiko, Minato, Nagahiro, Honjo, Tasuku |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6626008/ https://www.ncbi.nlm.nih.gov/pubmed/31300681 http://dx.doi.org/10.1038/s41598-019-46548-3 |
Ejemplares similares
-
Current issues and perspectives in PD-1 blockade cancer immunotherapy
por: Chamoto, Kenji, et al.
Publicado: (2020) -
Cancer immunotherapies targeting the PD-1 signaling pathway
por: Iwai, Yoshiko, et al.
Publicado: (2017) -
Facilitation of β Selection and Modification of Positive Selection in the Thymus of Pd-1–Deficient Mice
por: Nishimura, Hiroyuki, et al.
Publicado: (2000) -
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
por: Hamanishi, Junzo, et al.
Publicado: (2016) -
Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy
por: Kumar, Alok, et al.
Publicado: (2020)